AYTU NASDAQ
Aytu BioPharma, Inc.
1W: -9.2%
1M: -9.2%
3M: -5.5%
YTD: -25.3%
1Y: +10.7%
3Y: +7.8%
5Y: -96.5%
$2.07
-0.02 (-0.96%)
Weekly Expected Move ±6.2%
$2
$2
$2
$2
$2
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
20 relationships20
As Filer
counterparties named
0
As Counterparty
mentioned by others
4
Rel. Types
2021-04-05
Earliest Filing
2025-06-06
Latest Filing
customer: 12
partner: 6
investor: 1
acquirer: 1
Counterparties (Filed by AYTU)
20 relationshipsCompanies named in AYTU's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Lake Street Capital Markets, LLC | — | partner | Underwriter for the public offering of common stock and prefunded warrants. | 2025-06-06 | View |
| Fabre-Kramer Holdings, Inc. | — | partner | Exclusive Commercialization Agreement for EXXUA™ rights and obligations | 2025-06-06 | View |
| Nantahala Capital Management, LLC | — | investor | Investor in the offering with board appointment rights | 2023-06-12 | View |
| AMT Manufacturing Solutions, LLC | — | customer | Sublessee of Aytu BioPharma's manufacturing facility | 2023-05-01 | View |
| Canaccord Genuity LLC | — | partner | Underwriter for the issuance and sale of common stock, pre-funded warrants, and common stock purchase warrants. | 2022-03-04 | View |
| Neos Therapeutics, Inc. | — | customer | Borrower in the Avenue Capital Loan agreement | 2022-01-31 | View |
| Neos Therapeutics Brands, LLC | — | customer | Borrower in the Avenue Capital Loan agreement | 2022-01-31 | View |
| Neos Therapeutics, LP | — | customer | Borrower in the Avenue Capital Loan agreement | 2022-01-31 | View |
| Neos Therapeutics Commercial, LLC | — | customer | Borrower in the Avenue Capital Loan agreement | 2022-01-31 | View |
| PharmaFab Texas, LLC | — | customer | Borrower in the Avenue Capital Loan agreement | 2022-01-31 | View |
| Aytu Therapeutics, LLC | — | customer | Borrower in the Avenue Capital Loan agreement | 2022-01-31 | View |
| Innovus Pharmaceuticals, Inc. | — | customer | Borrower in the Avenue Capital Loan agreement | 2022-01-31 | View |
| Semprae Laboratories, Inc. | SREA | customer | Borrower in the Avenue Capital Loan agreement | 2022-01-31 | View |
| Novalere, Inc. | — | customer | Borrower in the Avenue Capital Loan agreement | 2022-01-31 | View |
| Supplement Hunt, Inc. | — | customer | Borrower in the Avenue Capital Loan agreement | 2022-01-31 | View |
| Delta Prime Savings Club, Inc. | — | customer | Borrower in the Avenue Capital Loan agreement | 2022-01-31 | View |
| UAB Caerus Biotechnologies | — | acquirer | Acquired intellectual property rights, technical information, and inventory related to MiOXSYS Analyzer and Sensors. | 2021-07-02 | View |
| Avrio Genetics, LLC | — | partner | Mutually terminated an exclusive license agreement and entered into a termination agreement. | 2021-07-02 | View |
| Cantor Fitzgerald & Co. | — | partner | Sales Agent for the Controlled Equity OfferingSM Sales Agreement | 2021-06-07 | View |
| Acerus Pharmaceuticals Corporation | — | partner | Termination and transition agreement to end license and supply relationship | 2021-04-05 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-09-22 | Earnings Release; Exhibits | View | |
| 2026-06-25 | Termination of Agreement | View | |
| 2026-05-13 | Earnings Release; Exhibits | View | |
| 2026-04-02 | Material Agreement; Earnings Release; Unregistered Equity Sales; Exhibits | Agreement | View |
| 2026-02-03 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-01-20 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-12-10 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-11-13 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-09-23 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-08-07 | Termination of Material Definitive Agreement | View | |
| 2025-06-23 | Entry into Material Definitive Agreement; Creation of Direct Financial Obligation; Regulation FD Dis | Agreement | View |
| 2025-06-17 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-06-09 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-06-06 | Entry into Material Definitive Agreement; Completion of Acquisition or Disposition of Assets; Regula | Agreement Acquisition | View |
| 2025-06-06 | Entry into Material Definitive Agreement; Regulation FD Disclosure; Financial Statements and Exhibit | Agreement | View |
| 2025-05-21 | Departure/Election of Directors; Appointment of Officers; Submission of Matters to a Vote of Securit | View | |
| 2025-05-14 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-02-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-12-04 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2024-11-13 | Results of Operations and Financial Condition; Departure/Election of Directors; Appointment of Offic | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR